10/20/2020 9:16:07 AM
Isoray Reports Pricing Of $9.5 Mln Public Offering
9/24/2019 4:08:35 PM
Isoray Q4 Loss/share $0.02 Vs. Loss $0.04 Year Ago
12/17/2018 8:14:46 AM
IsoRay Names Lori Woods CEO
12/3/2018 8:14:55 AM
IsoRay Appoints Jonathan Hunt As CFO
9/25/2018 4:16:08 PM
IsoRay Q4 Loss/share $0.04 Vs. Loss $0.03 Year Ago
7/12/2018 8:35:20 AM
IsoRay Closes $8.25 Mln Registered Direct Offering
6/19/2018 8:09:09 AM
IsoRay Announces Entry Into Employment Agreement With Lori Woods As Interim CEO
6/5/2018 8:08:14 AM
IsoRay Chairman And CEO Thomas LaVoy Resigns; Named Lori Woods Interim CEO; Mick McCormick Appointed Chairman
4/18/2018 8:36:09 AM
IsoRay Announces Q3 Preliminary Revenue Of $1.57 Mln, Up 23% Year-over-Year
1/24/2018 8:20:31 AM
IsoRay Q2 Preliminary Revenue $1.54 Mln Vs $1.03 Mln Last Year
1/8/2018 8:29:15 AM
IsoRay Signs Exclusive Manufacturing And Supply Agreement With GT Medical Technologies
11/9/2017 8:20:36 AM
IsoRay Announces The Launch Of A Phase II, Multicenter Trial With Cesium-131 Adjuvant Radiation
9/28/2017 8:08:04 AM
IsoRay Q4 Revenue $1.37 Mln, A 22% Increase From $1.12 Mln Last Year
8/4/2017 8:09:52 AM
IsoRay Q4 Preliminary Revenue $1.37 Mln Vs $1.12 Mln Last Year
7/6/2017 8:09:06 AM
IsoRay: FDA Indicates Need To Submit Addl Data As A Condition Of Securing FDA Clearance For Novel GammaTile Device
5/10/2017 8:08:00 AM
IsoRay Posts Q1 Net Loss Of $1.36 Mln Or $0.02/share
12/21/2016 8:38:22 AM
IsoRay Announces Launch Of Pilot Study Investigating The Role Of Cesium-131
11/8/2016 7:43:12 PM
IsoRay Q1 Revenue $1.08 Mln, 14% Decrease From Last Year